Direkt zum Inhalt
Merck

HCD8MAG-15K

Millipore

MILLIPLEX® Human CD8+ T Cell Magnetic Bead Panel - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonym(e):

Human CD8 T cell cytokine panel, Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12161503
eCl@ss:
32161000

Qualitätsniveau

Speziesreaktivität

human

Hersteller/Markenname

Milliplex®

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)

standard curve range: 0.5-2,000 pg/mL
(TNFα)

standard curve range: 1-3,500 pg/mL
(MIP-1α)

standard curve range: 1-5,000 pg/mL
(Granzyme B)

standard curve range: 1-5,000 pg/mL
(IFNγ)

standard curve range: 1-5,000 pg/mL
(IL-5)

standard curve range: 10-50,000 pg/mL
(Perforin)

standard curve range: 10-50,000 pg/mL
(sFasL)

standard curve range: 2-10,000 pg/mL
(IL-4)

standard curve range: 2-10,000 pg/mL
(sCD137)

standard curve range: 2-7,500 pg/mL
(IL-13)

standard curve range: 2-7,500 pg/mL
(IL-2)

standard curve range: 20-100,000 pg/mL
(Granzyme A)

standard curve range: 4-15,000 pg/mL
(GM-CSF)

standard curve range: 400-1,650,000 pg/mL
(sFas)

standard curve range: 5-20,000 pg/mL
(IL-10)

standard curve range: 7-30,000 pg/mL
(MIP-1β)

Methode(n)

multiplexing: suitable

Nachweisverfahren

fluorometric (Luminex xMAP)

Versandbedingung

wet ice

Allgemeine Beschreibung

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Spezifität

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Anwendung

  • Analytes: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, Perforin
  • Recommended Sample type: serum, plasma or tissue/cell lysate and culture supernatant
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight
  • Research Category Inflammation & Immunology

Leistungsmerkmale und Vorteile

Design your multiplex kit by choosing available analytes within this panel.

Lagerung und Haltbarkeit

Recommended storage for kit components is 2 - 8°C.

Sonstige Hinweise

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Rechtliche Hinweise

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Zielorgane

Respiratory Tract

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 3


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Wiebke Naujoks et al.
Frontiers in immunology, 11, 573200-573200 (2020-10-27)
Obesity is associated with an increased risk for several cancer types and an altered phenotype and functionality of natural killer (NK) cells. This study aimed to investigate the association of overweight and obesity with NK cell functions and receptor expression
Arturo Panduro et al.
Clinical liver disease, 19(2), 41-48 (2022-03-22)
Content available: Author Interview and Audio Recording.
Antti Hurme et al.
Frontiers in immunology, 13, 869990-869990 (2022-05-10)
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants
Chaoxu Zhang et al.
Frontiers in oncology, 10, 760-760 (2020-06-13)
Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects
Emily Han-Chung Hsiue et al.
Science (New York, N.Y.), 371(6533) (2021-03-03)
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.